Kiora Pharmaceuticals (KPRX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2025, with voting on director elections, executive compensation, and auditor ratification.

• Shareholders of record as of April 16, 2025, are eligible to vote, with 3,043,857 shares outstanding.

• Proxy materials and the 2024 Annual Report are available online; voting can be done online, by phone, mail, or in person.

Voting matters and shareholder proposals

• Election of two Class I directors for a three-year term.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of Haskell & White LLP as independent auditor for 2025.

• Shareholder proposals for the 2026 meeting must be submitted by December 31, 2025.

Board of directors and corporate governance

• Board consists of seven members divided into three staggered classes.

• Majority of directors are independent per Nasdaq rules.

• Separate CEO and non-executive chairman roles; regular executive sessions held.

• Board committees: audit, compensation, nominating and corporate governance, each with defined charters.

• Board diversity matrix and code of conduct in place.